Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation: A comment on Wallis and Detsky guest editorial.
作者信息
Paulden Mike, Mccabe Christopher
机构信息
School of Public Health; University of Alberta, Edmonton, AB, Canada.
Institute for Health Economics; University of Alberta, Edmonton, AB, Canada.
出版信息
Can Urol Assoc J. 2018 Mar;12(3):E163-E165. doi: 10.5489/cuaj.5119. Epub 2017 Dec 22.
Abstract
摘要
相似文献
1
Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation: A comment on Wallis and Detsky guest editorial.在医学创新评估中优先考虑成本效益的陷阱：对沃利斯和德茨基客座社论的评论
Can Urol Assoc J. 2018 Mar;12(3):E163-E165. doi: 10.5489/cuaj.5119. Epub 2017 Dec 22.
2
Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation.在医学创新评估中优先考虑成本效益的陷阱。
Can Urol Assoc J. 2018 Feb;12(2):7-8. doi: 10.5489/cuaj.5068. Epub 2017 Dec 1.
3
Goldman score, but not Detsky or Lee indices, predicts mortality 6 months after hip fracture.戈德曼评分可预测髋部骨折6个月后的死亡率，但德茨基指数或李指数则不能。
BMC Musculoskelet Disord. 2017 Apr 4;18(1):134. doi: 10.1186/s12891-017-1480-x.
4
Cost-Effectiveness in Global Surgery: Pearls, Pitfalls, and a Checklist.全球外科手术中的成本效益：要点、陷阱及清单
World J Surg. 2017 Jun;41(6):1401-1413. doi: 10.1007/s00268-017-3875-0.
5
The Quality of Randomized Controlled Trials in Pediatric Orthopaedics: Are We Improving?小儿骨科随机对照试验的质量：我们是否在进步？
J Pediatr Orthop. 2015 Jul-Aug;35(5):536-45. doi: 10.1097/BPO.0000000000000324.
6
Guest Editorial Advanced Practice Leadership and Innovation.客座编辑 高级实践领导力与创新
Nurs Adm Q. 2017 Jan/Mar;41(1):2-3. doi: 10.1097/NAQ.0000000000000211.
7
Comment on guest editorial: "Models and model analysis".关于特邀社论《模型与模型分析》的评论
Ground Water. 2010 Nov-Dec;48(6):785. doi: 10.1111/j.1745-6584.2010.00731.x.
8
Imagery and cognition (special issue): guest editorial comment.
Neurosci Biobehav Rev. 2008 Oct;32(8):1337-8. doi: 10.1016/j.neubiorev.2008.05.022. Epub 2008 May 23.
9
Comment on guest editorial: "Role of ethics in groundwater management".
Ground Water. 2010 Jul-Aug;48(4):480-1; discussion 481. doi: 10.1111/j.1745-6584.2010.00700.x.
10
Guest editorial. Innovations in transforming organizations.客座社论。组织转型中的创新。
Nurs Adm Q. 2009 Jul-Sep;33(3):195-6. doi: 10.1097/01.NAQ.0000356836.68054.3b.
本文引用的文献
1
Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation.在医学创新评估中优先考虑成本效益的陷阱。
Can Urol Assoc J. 2018 Feb;12(2):7-8. doi: 10.5489/cuaj.5068. Epub 2017 Dec 1.
2
Robotic Surgical System for Radical Prostatectomy: A Health Technology Assessment.用于根治性前列腺切除术的机器人手术系统：一项卫生技术评估。
Ont Health Technol Assess Ser. 2017 Jul 7;17(11):1-172. eCollection 2017.
3
Accountability for reasonableness: an update.合理性问责制：最新情况
BMJ. 2008 Oct 9;337:a1850. doi: 10.1136/bmj.a1850.
4
Ontario's formulary committee: how recommendations are made.安大略省药品目录委员会：建议是如何制定的。
Pharmacoeconomics. 2003;21(4):285-94. doi: 10.2165/00019053-200321040-00006.
Zotero 插件